RESEARCHER PROFILE
Selım Gürel
← Back to Bursa Uludağ Üni̇versi̇tesi̇
S
Bursa Uludağ Üni̇versi̇tesi̇
Selım Gürel works in Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, Helicobacter pylori-related gastroenterology studies, Liver Disease and Transplantation. Recorded institutional associations include Bursa Uludağ Üni̇versi̇tesi̇.
202Publications
5,081Citations
26H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004 · 1,145 citationsPeginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
2011 · 488 citationsThree-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
2010 · 462 citationsSustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
2009 · 315 citationsLate HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
2014 · 301 citationsSeven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
2014 · 297 citationsPredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
2006 · 261 citationsImpact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
2015 · 212 citationsPeginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
2019 · 199 citationsRandomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B
2013 · 148 citationsQuantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
2009 · 120 citationsKinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate
2014 · 116 citationsFamciclovir treatment of chronic delta hepatitis
2002 · 111 citationsTen‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta
2020 · 80 citationsAnti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta
2014 · 68 citationsAssociation Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome
2015 · 66 citationsTenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
2016 · 62 citationsLong-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
2015 · 60 citationsIs severe cryptogenic chronic hepatitis similar to autoimmune hepatitis?
1998 · 59 citationsO4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY
2014 · 57 citationsTWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS
2008 · 57 citations43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA
2013 · 37 citationsPegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis B
2007 · 36 citationsAnti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment
2011 · 32 citations924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP
2009 · 27 citations
